Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Trisha Smith

Family Medicine Fort Worth, TX Medical Doctor

NPI 1255359360 CMS profile 102439

855 Montgomery St, Fort Worth, TX 76107

Open in the dashboard

General payments

$4,646

300 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Trisha Smith of Fort Worth, TX is reported in the CMS Open Payments database as having received $4,646 across 300 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $71 3
2022 General $305 17
2021 General $1,805 121
2020 General $1,160 75
2019 General $1,305 84

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Trisha Smith
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Trisha Smith were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Trisha Smith Family Medicine median Middle half National median
2019 $1,305 $150 $41–$543 $163
2020 $1,160 $120 $32–$415 $114
2021 $1,805 $137 $35–$551 $132
2022 $305 $137 $37–$512 $149
2023 $71 $149 $42–$545 $160
2024 $0 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Novo Nordisk Inc $613 47 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $416 29 payments
  3. Amarin Pharma Inc. $363 23 payments
  4. AbbVie, Inc. $346 26 payments
  5. AstraZeneca Pharmaceuticals LP $302 21 payments
  6. Astellas Pharma US Inc $302 10 payments
  7. Esperion Therapeutics, Inc. $278 10 payments
  8. Amgen Inc. $264 20 payments
  9. Allergan Inc. $198 15 payments
  10. Janssen Pharmaceuticals, Inc $161 6 payments
  11. Other $1,403 93 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $4,557 297 payments
  2. Education $90 3 payments
Products named General payments · program years 2019–2023
  1. Ozempic $510 40 payments
  2. JARDIANCE $393 28 payments
  3. RYBELSUS $288 22 payments
  4. NEXLETOL $278 10 payments
  5. Vascepa $276 18 payments
  6. MYRBETRIQ $227 9 payments
  7. FARXIGA $225 15 payments
  8. XARELTO $161 6 payments
  9. Repatha $157 12 payments
  10. UBRELVY $135 9 payments
  11. Other $3,669 269 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$3,679

Medicare's payments for the services billed

Medicare patients

29

Average age 73

Services billed

39

16 women, 13 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Heart failure 52%
Chronic kidney disease 48%
Diabetes 45%
Depression 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

300 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record